Provided by Tiger Trade Technology Pte. Ltd.

NEWAMSTERDAM PHARMA CO NV

22.79
-2.8400-11.08%
Pre-market: 22.790.00000.00%08:32 EDT
Volume:2.32M
Turnover:53.68M
Market Cap:2.72B
PE:-10.63
High:25.53
Open:25.35
Low:22.34
Close:25.63
52wk High:42.21
52wk Low:22.34
Shares:119.54M
Float Shares:92.51M
Volume Ratio:1.71
T/O Rate:2.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1442
EPS(LYR):-1.7211
ROE:-36.81%
ROA:-20.11%
PB:4.31
PE(LYR):-13.24

Loading ...

NewAmsterdam Pharma Price Target Maintained with a $52.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), NewAmsterdam Pharma Company (NAMS) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Sep 08

Why the Dow is Being Dragged Down by a Swiss Company's Bad News

Dow Jones
·
Sep 08

Novartis Cholesterol Setback Tests Hopes for Emerging Heart Disease Drugs

Reuters
·
Sep 07

Newamsterdam Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Sep 04

NewAmsterdam Pharma Grants Inducement Share Options for 52,900 Shares at $24.92 Each

Reuters
·
Sep 04

NewAmsterdam Pharma to Present Phase 3 Obicetrapib Trial Data at ESC Congress 2026

Reuters
·
Aug 26

NewAmsterdam Pharma CSO Johannes Kastelein Disposes of 125,000 Shares for USD 3.36 Million

Reuters
·
Aug 26

NewAmsterdam Pharma Amends 8-K to Disclose COO Douglas Kling Separation, Advisor Agreement Terms

Reuters
·
Aug 15

NewAmsterdam Pharma Appoints Robert Gunning Principal Accounting Officer

Reuters
·
Aug 15

Needham Remains a Buy on NewAmsterdam Pharma Company (NAMS)

TIPRANKS
·
Aug 08

NewAmsterdam Pharma Grants 28,000 Inducement Share Options at $27.79 to New Hires

Reuters
·
Aug 07

RBC Adjusts NewAmsterdam Pharma PT to $50 From $51, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
Aug 06

Stifel Nicolaus Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

TIPRANKS
·
Aug 06

NewAmsterdam Pharma Company N.V. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion for Obicetrapib and Obicetrapib/Ezetimibe

Reuters
·
Aug 05

NewAmsterdam Pharma Q2 EPS $(0.52) Misses $(0.48) Estimate, Sales $3.701M Beat $1.663M Estimate

Benzinga Earnings
·
Aug 05

NewAmsterdam Pharma Q2 Net Loss Widens to USD 64.1 Million; Revenue Falls to USD 3.7 Million

Reuters
·
Aug 05

Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Dow Jones
·
Aug 05

Why NewAmsterdam Pharma (NAMS) Is Down 6.2% After EMA Backs Ubeslo And Evlarco Approval

Simply Wall St.
·
Aug 03